ArticleFrontiers in immunology2023
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Convalescent plasma therapy for COVID-19 prophylaxis in adults early post-hematopoietic stem cell transplantation: one-year outcomes from a randomized controlled trial.Frontiers in immunology · 2025Trial
- 30 years in service, 1996-2026: Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Annals of hematology · 2026Review
- Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the "Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare" (GITMO).American journal of hematology · 2025Article
- Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis.Bone marrow transplantation · 2025Article
- Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective.Infectious diseases and therapy · 2025Review
- Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.American journal of hematology · 2025Article
- COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics.Transplantation and cellular therapy · 2024Article
- Pulmonary complications of bone marrow transplantation.Breathe (Sheffield, England) · 2024Review
- Pre-existing Immunocompromising Conditions and Outcomes of Acute COVID-19 Patients Admitted for Pediatric Intensive Care.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Persistent Impairment in Immune Reconstitution and Worse Survival Outcomes in Allogeneic Stem Cell Transplantation Patients with Early Coronavirus Disease 2019 Infection.Transplantation and cellular therapy · 2024Article
- Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre-Cellular Therapy SARS-CoV-2 Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.Infection · 2024Article
- COVID-19 was associated with the complications after allogeneic hematopoietic stem cell transplantation.Scientific reports · 2024Article
- Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.EClinicalMedicine · 2024Article
- COVID-19 in immunocompromised patients after hematopoietic stem cell transplantation: a pilot study.Blood science (Baltimore, Md.) · 2024Article
- Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.Transplantation and cellular therapy · 2024Article
- Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report.Frontiers in oncology · 2024Article
- Article
- Updated COVID-19 clearance time among patients with cancer in the Delta and Omicron waves.Cancer medicine · 2023Article
- Acute Myeloid Leukemia Survivors Report Transplant-specific Burdens in Interviews Two Years after Receiving Allogeneic Hematopoietic Cell Transplantation During the Peak of the COVID-19 Pandemic: A Qualitative Study.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
56 authors at 20 institutions in 15 countries.
Alessandro BuscaStem Cell Transplant Center, AOU Citta' della Salute e della Scienza, Turin, Italy.
Jon Salmanton-GarcíaUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Francesco MarchesiHematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Francesca FarinaIRCCS Ospedale San Raffaele, Milan, Italy.
Guldane Cengiz SevalAnkara University, Ankara, Türkiye.
Jaap Van DoesumUniversity Medical Center Groningen, Groningen, Netherlands.
Nick De JongeAmsterdam UMC, Amsterdam, Netherlands.
Nathan C BahrUniversity of Kansas Medical Center, Kansas, KS, United States.
Johan MaertensDepartment of Microbiology, Immunology, and Transplantation, KULeuven, Leuven, Belgium.
Joseph MeletiadisClinical Microbiology Laboratory, Medical School, "Attikon" University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Nicola S FracchiollaFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Barbora WeinbergerováDepartment of Internal Medicine - Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czechia.
Luisa VergaAzienda Ospedaliera San Gerardo - Monza, Monza, Italy.
Zdeněk RáčilInstitute of Hematology and Blood Transfusion, Prague, Czechia.
Moraima JiménezDepartment of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital, Barcelona, Spain.
Andreas GlenthøjDepartment of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Ola BlennowDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Alina Daniela TanaseFundeni Clinical Institute, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Martin SchönleinDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Lucia PreziosoHospital University of Parma - Hematology and Bone Marrow Unit, Parma, Italy.
Nina KhannaDivision of Infectious Diseases and Hospital Epidemiology, and Department of Clinical Research, University and University Hospital of Basel, Basel, Switzerland.
Rafael F DuarteHospital Universitario Puerta de Hierro, Majadahonda, Spain.
Pavel ŽákUniversity Hospital Hradec Králové, Hradec Králové, Czechia.
Marcio NucciFederal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Marina MachadoClinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Austin KulasekararajKing's College Hospital, London, United Kingdom.
Ildefonso EspigadoDepartment of Hematology, University Hospital Virgen Macarena - University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla (Departamento de Medicina), Seville, Spain.
Elizabeth De KortRadboudumc, Nijmegen, Netherlands.
José-María Ribera-Santa SusanaClinical Hematology Department, ICO-Hospital germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain.
Monia MarchettiAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Gabriele MaglianoASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Iker Falces-RomeroLa Paz University Hospital, Madrid, Spain.
Osman IlhanAnkara University, Ankara, Türkiye.
Emanuele AmmatunaUniversity Medical Center Groningen, Groningen, Netherlands.
Sofia ZompiStem Cell Transplant Center, AOU Citta' della Salute e della Scienza, Turin, Italy.
Panagiotis TsirigotisClinical Microbiology Laboratory, Medical School, "Attikon" University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Anastasia AntoniadouClinical Microbiology Laboratory, Medical School, "Attikon" University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Giovanni Paolo Maria ZambrottaAzienda Ospedaliera San Gerardo - Monza, Monza, Italy.
Anna NordlanderDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Linda Katharina KarlssonDepartment of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Michaela HanakovaInstitute of Hematology and Blood Transfusion, Prague, Czechia.
Giulia DragonettiHematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.
Alba CabirtaDepartment of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital, Barcelona, Spain.
Caroline Berg VenemyrDepartment of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Stefanie GräfeUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Jens Van PraetDepartment of Nephrology and Infectious diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium.
Athanasios TragiannidisAristotle University of Thessaloniki, Thessaloniki, Greece.
Verena PetzerDepartment of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
Alberto López-GarcíaFundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain.
Federico ItriSan Luigi Gonzaga Hospital - Orbassano, Orbassano, Italy.
Ana GrohInfektiologie, Universitätsklinikum Frankfurt am Main, Frankfurt am Main, Germany.
Eleni GavriilakiGeneral Hospital of Thessaloniki "George Papanikolaou", Thessaloniki, Greece.
Michelina DargenioHematology and Stem Cell Transplant Unit, Vito Fazzi, Lecce.
Laman RahimliUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Oliver A CornelyUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Livio PaganoHematology Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
University of Cologne · DECopenhagen University Hospital · DKNational and Kapodistrian University of Athens · GRAnkara University · TRAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliera San Gerardo · ITInstitute of Haematology and Blood Transfusion · CZKarolinska University Hospital · SEUniversity Medical Center Groningen · NLAgostino Gemelli University Polyclinic · ITAmsterdam University Medical Centers · NLAristotle University of Thessaloniki · GRAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITAZ Sint-Jan · BEFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITGoethe University Frankfurt · DEG. Papanikolaou General Hospital · GRHospital General Universitario Gregorio Marañón · ESHospital Universitario Fundación Jiménez Díaz · ES
Funding
Novel Diagnostic Development for TB Meningitis and HistoplasmosisK23NS110470 · NINDS · UNIVERSITY OF MINNESOTA · PI BAHR, NATHAN · 2019 to 2023
$1.0MNINDS NIH HHS K23 NS110470
Abstract
Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association - Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
Indexed as
COVID-19Hematologic DiseasesHematopoietic Stem Cell TransplantationAdultHumansMiddle AgedRetrospective StudiesStem Cell Transplantationallogeneic HSCTCOVID-19 infectionhematological malignancesimmunocompromised patientsSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.